Abemaciclib for pre/perimenopausal women with HR+, HER2-advanced breast cancer

被引：13
|
作者：
Neven, Patrick
Rugo, Hope S.
Tolaney, Sara M.
Iwata, Hiroji
Toi, Masakazu
Goetz, Matthew P.
Kaufman, Peter A.
Barriga, Susana
Lin, Yong
Sledge, George W.
机构：
[1] Univ Hosp Leuven, Leuven, Belgium
[2] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[5] Kyoto Univ, Grad Sch Med, Dept Surg, Kyoto, Japan
[6] Mayo Clin, Rochester, MN USA
[7] Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, Lebanon, NH 03766 USA
[8] Eli Lilly & Co, Madrid, Spain
[9] Eli Lilly & Co, Indianapolis, IN 46285 USA
[10] Stanford Univ, Sch Med, Stanford, CA 94305 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.1002
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1002
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Cost-effectiveness analysis of ribociclib in the treatment for premenopausal or perimenopausal women with HR+/HER2-advanced breast cancer: a public health care system perspective in Mexico
    Campos-Gomez, Saul
    Pina, Christian Pichardo
    CANCER RESEARCH, 2024, 84 (09)
  • [42] Cost-effectiveness comparison of dalpiciclib and abemaciclib combined with an aromatase inhibitor as first-line treatment for HR+/HER2-advanced breast cancer
    Hong, Juan
    Chen, Tujia
    Ouyang, Lihui
    Du, Ning
    Li, Anna
    Zhou, Zhongqi
    Zhang, HaiLing
    Xia, Zhengzheng
    Meng, Jun
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2024, 24 (04) : 559 - 566
  • [43] HR+/HER2-Advanced Breast Cancer Treatment in the First-Line Setting: Expert Review
    Jerzak, Katarzyna J.
    Bouganim, Nathaniel
    Brezden-Masley, Christine
    Edwards, Scott
    Gelmon, Karen
    Henning, Jan-Willem
    Hilton, John F.
    Sehdev, Sandeep
    CURRENT ONCOLOGY, 2023, 30 (06) : 5425 - 5447
  • [44] Patterns and outcomes in HR+/HER2-advanced/metastatic breast cancer patients in Brazil receiving palbociclib
    Simon, Patricia
    Jain, Ankita
    Guarin, Alexandra
    Piton, Luciana
    Carvalho, Carla Fabrine
    Lima, Julia
    Nazareth, Felipe
    FUTURE ONCOLOGY, 2024,
  • [45] The prognostic impact of BMI in patients with HR+/HER2-advanced breast cancer: a study of the SONABRE registry
    Lammers, Senna W. M.
    Thurisch, Hannah
    Vriens, Ingeborg J. H.
    Meegdes, Marissa
    Engelen, Sanne M. E.
    Erdkamp, Frans L. G.
    Dercksen, M. Wouter
    Vriens, Birgit E. P. J.
    Aaldering, Kirsten N. A.
    Pepels, Manon J. A. E.
    van de Winkel, Linda M. H.
    Peters, Natascha A. J. B.
    Tol, Jolien
    Heijns, Joan B.
    van de Wouw, Agnes J.
    Teeuwen, Nathalie J. A.
    Geurts, Sandra M. E.
    Tjan-Heijnen, Vivianne C. G.
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 203 (02) : 339 - 349
  • [46] Current treatment landscape of HR+/HER2-advanced breast cancer in the Nordics: A modified Delphi study
    Karihtala, P.
    Valachis, A.
    Tuxen, M.
    Geisler, J.
    ANNALS OF ONCOLOGY, 2022, 33 : S218 - S218
  • [47] Current treatment landscape of HR+/HER2-advanced breast cancer in the Nordics: a modified Delphi study
    Geisler, Jurgen
    Karihtala, Peeter
    Tuxen, Malgorzata
    Valachis, Antonis
    Holm, Barbro
    ACTA ONCOLOGICA, 2023, 62 (12) : 1680 - 1688
  • [48] Cost-Effectiveness Analysis of Abemaciclib Plus Fulvestrant in the Second-Line Treatment of Women With HR+/HER2-Advanced or Metastatic Breast Cancer: A US Payer Perspective
    Wang, Yingcheng
    Rui, Mingjun
    Guan, Xin
    Cao, Yingdan
    Chen, Pingyu
    FRONTIERS IN MEDICINE, 2021, 8
  • [49] A systematic literature review of prognostic factors in patients with HR+/HER2-advanced breast cancer in Japan
    Hattori, Masaya
    Novick, Diego
    Takaura, Kana
    Tanizawa, Yoshinori
    Kawaguchi, Tsutomu
    Haro, Josep Maria
    Monistrol-Mula, Anna
    Onishi, Akira
    Iwata, Hiroji
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (10) : 1498 - 1508
  • [50] CLINICAL AND ECONOMIC ANALYSIS OF EFFECTIVENESS OF EVEROLIMUS IN THE TREATMENT OF HR+, HER2-ADVANCED BREAST CANCER IN RUSSIA
    Krasnova, L.
    Vorobiev, P.
    Holownia, M.
    VALUE IN HEALTH, 2014, 17 (07) : A635 - A635
12345